Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA

Table 1 Measures evaluated in order to reach the outcomes

Time point	Data collection	Measure	Outcomes
At rest	Continuous glucose monitoring system	Glucose values	Glucose variability
	Vascular Doppler ultrasound	Flow-mediated dilatation	Endothelial function
	Blood sampling	Glucagon, glucose, HbA1c, insulin and GLP-1	Metabolic responses
	Impedance cardiography and electrocardiogram	Cardiac output, heart rate	Cardiovascular response
	24 hour urine	F2 isoprostane 8-isoprostaglandin F2α/ creatinine	Oxidative stress
During submaximal exercise tests	Continuous glucose monitoring system	Glucose values	Glucose variability
	Impedance cardiography and electrocardiogram	^aCardiac output, heart rate	Cardiovascular response to exercise
	Blood sampling	^aGlucagon, glucose, insulin, and GLP-1	Metabolic responses
After submaximal exercise tests	Continuous glucose monitoring system	Glucose values	Glucose variability
	Impedance cardiography and electrocardiogram	^abCardiac output, heart rate	Cardiovascular response to exercise
	Ambulatory blood pressure monitoring	24 hour blood pressure variability	Cardiovascular response to exercise
	Blood sampling	^abGlucagon, glucose, insulin and GLP-1	Metabolic responses

GLP-1, glucagon-like peptide 1; HbA1c, glycated hemoglobin. ^a0, 15, and 30 minutes; ^ab60 minutes after exercise.

ISSN: 1745-6215